Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | WX-0593 |
| Synonyms | |
| Therapy Description |
WX-0593 (iruplinalkib) inhibits ALK and ROS1, with additional activity against EGFR mutations, which may lead to decreased tumor growth (PMID: 35087031; Cancer Res 2018;78(13 Suppl):Abstract nr 4794). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| WX-0593 | WX0593|WX 0593|FL 006|FL-006|FL006|Iruplinalkib | ALK Inhibitor 29 EGFR Inhibitor (Pan) 55 ROS1 Inhibitor 19 | WX-0593 (iruplinalkib) inhibits ALK and ROS1, with additional activity against EGFR mutations, which may lead to decreased tumor growth (PMID: 35087031; Cancer Res 2018;78(13 Suppl):Abstract nr 4794). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK ALK F1174C | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 treatment inhibited viability of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 35421578). | 35421578 |
| EML4 - ALK ALK F1174L | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 treatment inhibited viability of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 35421578). | 35421578 |
| EML4 - ALK ALK T1151dup | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 treatment inhibited viability of transformed cells expressing EML4-ALK with ALK T1151dup in culture (PMID: 35421578). | 35421578 |
| EML4 - ALK ALK V1180L | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 treatment inhibited viability of transformed cells expressing EML4-ALK with ALK V1180L in culture (PMID: 35421578). | 35421578 |
| EML4 - ALK ALK I1171N | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 treatment inhibited viability of transformed cells expressing EML4-ALK with ALK I1171N in culture (PMID: 35421578). | 35421578 |
| EML4 - ALK ALK L1152P | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 treatment inhibited viability of transformed cells expressing EML4-ALK with ALK L1152P in culture (PMID: 35421578). | 35421578 |
| ALK rearrange | lung non-small cell carcinoma | sensitive | WX-0593 | Phase I | Actionable | In a Phase I trial, WX-0593 (iruplinalkib) demonstrated safety and resulted in an objective response rate (ORR) of 56.6% (56/99; all partial responses) and a disease control rate (DCR) of 83.8% (83/99), and median duration of response and median progression-free survival were not reached in non-small cell lung cancer patients with an ALK or ROS1-rearrangement, with an ORR of 58.2% (53/91; all partial responses) and DCR of 85.7% (78/91) in patients with an ALK rearrangement (PMID: 35087031; NCT03389815). | 35087031 |
| EML4 - ALK ALK I1171S | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 treatment inhibited viability of transformed cells expressing EML4-ALK with ALK I1171S in culture (PMID: 35421578). | 35421578 |
| EML4 - ALK ALK G1202R | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 treatment inhibited viability of transformed cells expressing EML4-ALK with ALK G1202R in culture (PMID: 35421578). | 35421578 |
| EML4 - ALK | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 35421578). | 35421578 |
| EML4 - ALK | lung non-small cell carcinoma | sensitive | WX-0593 | Preclinical - Pdx | Actionable | In a preclinical study, WX-0593 inhibited tumor growth in a patient-derived xenograft (PDX) model of non-small cell lung cancer harboring EML4-ALK (PMID: 35421578). | 35421578 |
| EML4 - ALK ALK F1174V | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 treatment inhibited viability of transformed cells expressing EML4-ALK with ALK F1174V in culture (PMID: 35421578). | 35421578 |
| EML4 - ALK ALK L1196M | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 inhibited growth of transformed cells expressing ALK L1196M in the context of EML4-ALK in culture (PMID: 35421578). | 35421578 |
| ROS1 rearrange | lung non-small cell carcinoma | sensitive | WX-0593 | Phase I | Actionable | In a Phase I trial, WX-0593 (iruplinalkib) demonstrated safety and resulted in an objective response rate (ORR) of 56.6% (56/99; all partial responses) and a disease control rate (DCR) of 83.8% (83/99), and median duration of response and median progression-free survival were not reached in non-small cell lung cancer patients with an ALK or ROS1-rearrangement, with an ORR of 44.4% (4/9) and DCR of 66.7% (6/9) in patients with a ROS1 rearrangement (PMID: 35087031). | 35087031 |
| EML4 - ALK ALK I1171T | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 treatment inhibited viability of transformed cells expressing EML4-ALK with ALK I1171T in culture (PMID: 35421578). | 35421578 |
| EML4 - ALK ALK G1269A | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 treatment inhibited viability of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 35421578). | 35421578 |
| EML4 - ALK ALK C1156Y | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 inhibited growth of transformed cells expressing ALK C1156Y in the context of EML4-ALK in culture (PMID: 35421578). | 35421578 |
| EML4 - ALK ALK L1152R | Advanced Solid Tumor | sensitive | WX-0593 | Preclinical - Cell culture | Actionable | In a preclinical study, WX-0593 treatment inhibited viability of transformed cells expressing EML4-ALK with ALK L1152R in culture (PMID: 35421578). | 35421578 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST